Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	100167
Country	South Korea

Received	2024-08-13 14:45
Peer-Review Started	2024-08-13 14:45
To Make the First Decision
Return for Revision	2024-11-11 07:27
Revised	2024-11-27 07:12
Second Decision	2024-12-10 02:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-10 06:15
Articles in Press	2024-12-10 06:15
Publication Fee Transferred	2024-11-28 13:35
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-12-17 09:07
Publish the Manuscript Online	2025-01-18 08:12

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Retrospective Study
Article Title	Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy
Manuscript Source	Unsolicited Manuscript
All Author List	Bomi Kim, Jaihwan Kim, Soomin Yang, Jinwoo Ahn, Kwangrok Jung, Jong-Chan Lee and Jin-Hyeok Hwang
ORCID	Author(s) ORCID Number Bomi Kim http://orcid.org/0000-0001-5690-5923 Jaihwan Kim http://orcid.org/0000-0003-0693-1415 Jinwoo Ahn http://orcid.org/0000-0001-6425-2723 Jong-Chan Lee http://orcid.org/0000-0001-6590-2353 Jin-Hyeok Hwang http://orcid.org/0000-0002-5643-8461
Funding Agency and Grant Number
Corresponding Author	Jaihwan Kim, MD, PhD, Professor, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Seongnam 13620, South Korea. drjaihwan@snu.ac.kr
Key Words	Pancreatic cancer; Chemotherapy; Survival; Performance status; Carbohydrate antigen 19-9
Core Tip	This study retrospectively analyzed 141 patients with advanced pancreatic cancer treated between 2012 and 2021, who underwent first-line oxaliplatin or gemcitabine plus nab-paclitaxel, followed by third-line chemotherapy. The median overall survival was 19 months, with 15.3 weeks after third-line treatment. The study identified that patients with good performance status, carbohydrate antigen 19-9 < 1000 U/mL, second-line chemotherapy ≥ 19 weeks, and no peritoneal seeding before starting third-line treatment had better outcomes regardless of the third-line regimen. These findings suggest that such patients may benefit more from third-line chemotherapy in spite of unsatisfactory treatment results from all patients.
Publish Date	2025-01-18 08:12
Citation	<p>Kim B, Kim J, Yang S, Ahn J, Jung K, Lee JC, Hwang JH. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. <i>World J Gastrointest Oncol</i> 2025; 17(2): 100167</p>
URL	https://www.wjgnet.com/1948-5204/full/v17/i2/100167.htm
DOI	https://dx.doi.org/10.4251/wjgo.v17.i2.100167

Full Article (PDF)	WJGO-17-100167-with-cover.pdf
Manuscript File	100167_Auto_Edited_083720.docx
Answering Reviewers	100167-answering-reviewers.pdf
Audio Core Tip	100167-audio.mp3
Biostatistics Review Certificate	100167-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	100167-conflict-of-interest-statement.pdf
Copyright License Agreement	100167-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	100167-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	100167-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	100167-non-native-speakers.pdf
Supplementary Material	100167-supplementary-material.pdf
Peer-review Report	100167-peer-reviews.pdf
Scientific Misconduct Check	100167-scientific-misconduct-check.png
Scientific Editor Work List	100167-scientific-editor-work-list.pdf
CrossCheck Report	100167-crosscheck-report.png
CrossCheck Report	100167-crosscheck-report.pdf